Imatinib vs Ipilimumab
Imatinib vs Ipilimumab: Overview
This comparison examines the pharmacological differences between Imatinib and Ipilimumab.
Mechanism of Action
Imatinib: Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Imatinib — 18 hours; Ipilimumab — 14.7 days.
Chemical Properties
Molecular Formula: Imatinib — C29H31N7O.
Molecular Weight: Imatinib — 493.6030 g/mol.
Type: Imatinib — Small molecule; Ipilimumab — Antibody.